Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Richard Syzdlo"'
Autor:
Alice C J Hart, Ana Maria Cabrera, Camelia Vladescu, Sobia Mustafa, Richard Syzdlo, Rocel C. Saputil, Michelle MH Tan, Amna Malik, David Sharp, Pedro Vicente, Albert Busza, Michael Laffan, Anastasia Gontsarova, Adam Waldman, Nichola Cooper
Publikováno v:
Blood. 140:48-49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e24c28bb12e574c25ecb0edce071d474
https://doi.org/10.1182/blood-2022-158176
https://doi.org/10.1182/blood-2022-158176
Autor:
Camelia Vladescu, Alice C J Hart, Deena Paul, Christine Ademokun, Ariam Teklemichael, Bridget Chivers, Billy Hopkins, Richard Syzdlo, Naghma Rizvi, Vashti Ragoonanan, Sandra Sigudu, James B. Bussel, Anastastia Gontsarova, Adam Waldman, Nichola Cooper
Publikováno v:
Blood. 140:5553-5554
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5052c48a11c93d409eef6d2fbb2e3af
https://doi.org/10.1182/blood-2022-166412
https://doi.org/10.1182/blood-2022-166412
Autor:
Trudy Ahyee, Richard Syzdlo, C Navarette, Elisabeth P. Nacheva, Rachel Pawson, Juanah Addada, Stephen Mackinnon, J. Alejandro Madrigal, Bronwen E. Shaw
Publikováno v:
Blood. 134:4474-4474
Granulocyte-Colony-Stimulating factor (G-CSF) is currently the standard mobilizing agent for peripheral blood stem cell (PBSC) donation. While G-CSF use is associated with mild transient side-effects, concerns that it may trigger hematological malign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e75401d8dbafbc40761d0e1e8b0823b
https://doi.org/10.1182/blood-2019-131931
https://doi.org/10.1182/blood-2019-131931
Autor:
Nicholas Latimer, Christopher Pocock, Leanne M. Cork, Jennifer Byrne, Wendy Osborne, Stephen J. O'Brien, Letizia Foroni, Ruth V. Bescoby, James Wason, Valeria Bandeira, Mhairi Copland, Thomas Zwingers, Jane F. Apperley, Bernard Ramsahoye, Richard Syzdlo, Richard E. Clark, Lynn Alaily, Corinne Hedgley, Helen Bell-Gorrod
Publikováno v:
Blood. 132:457-457
Objective. SPIRIT 2 is the largest phase 3 prospective randomized open-label trial comparing imatinib (I) 400mg with dasatinib (D) 100mg daily in newly diagnosed chronic phase CML. The primary endpoint was 5 year event-free survival. Methods. 812 (40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f599c25b9a3af764079b510d97855dc3
https://doi.org/10.1182/blood-2018-99-110128
https://doi.org/10.1182/blood-2018-99-110128
Autor:
Farah O'Boyle, Mark Robinson, Marco Bua, Kikkeri N. Naresh, Anastasios Karadimitris, Eva Yebra-Fernandez, Holger W. Auner, Syeda Maheen Ahsan, Aristeidis Chaidos, Richard Syzdlo, Maria Atta, Elisabet Nadal-Melsio, Jane F. Apperley
Publikováno v:
Blood. 132:4492-4492
Background: Multiple myeloma (MM) is a remitting-relapsing malignancy with variable clinical outcome. Certain cytogenetic abnormalities, either present at diagnosis or emerged at later stages, predict for poor outcome and highlight the clinical impor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed75289021d20c181dd880fceeb782cd
https://doi.org/10.1182/blood-2018-99-117460
https://doi.org/10.1182/blood-2018-99-117460
Autor:
Simone Claudiani, Philippa Woolley, Richard Syzdlo, Eduardo Olavarria, David Slade, Edward Kanfer, George Nesr, Irene Caballes, Fiona Fernando, Jane F. Apperley, Dragana Milojkovic, Jiri Pavlu, Renuka Palani
Publikováno v:
Blood. 132:5746-5746
Introduction: Ex-Vivo T-Cell Depletion (EX-TCD) has been shown, in multiple cohorts, to markedly decrease the incidence of graft-versus-host-disease (GvHD). This conditioning regime however, has been associated with high incidence of disease relapse.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2f29f5d5c05f17e7cf90cae25c14d0d
https://doi.org/10.1182/blood-2018-99-114420
https://doi.org/10.1182/blood-2018-99-114420